<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02932566</url>
  </required_header>
  <id_info>
    <org_study_id>2016CD004</org_study_id>
    <nct_id>NCT02932566</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction</brief_title>
  <acronym>PIROUETTE</acronym>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction (PIROUETTE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manchester University NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool, Clinical Trials Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Therapeutics Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Manchester University NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomised, double-blind, placebo-controlled, phase 2 study aims to evaluate the
      efficacy and safety of the anti-fibrotic drug pirfenidone in the treatment of patients with
      heart failure and preserved left ventricular ejection fraction (HFpEF). Participants will be
      randomised to receive either pirfenidone or placebo, for a period of 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myocardial fibrosis is a key pathological mechanism in HFpEF. Pirfenidone is an anti-fibrotic
      medication licensed for the treatment of idiopathic lung fibrosis, for which it reduces lung
      function decline, improves progression free survival and reduces all cause mortality. In
      pre-clinical models, pirfenidone attenuates profibrotic pathways and is associated with
      regression of myocardial fibrosis. Previous studies in HFpEF populations using anti-fibrotic
      medications, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II receptor
      blockers and aldosterone antagonists have shown some benefit in reaching secondary end-points
      but do not reduce mortality. HFpEF is the final result of a number of specific underlying
      pathological mechanisms, and targeted treatment of these mechanisms has been cited as the
      future approach to further clinical trials. The investigators aim to select a population of
      HFpEF patients with high levels of interstitial myocardial fibrosis as measured on cardiac
      MRI (CMR), and randomise participants to receive pirfenidone or placebo. The primary outcome
      is to detect a significant reduction in myocardial fibrosis as measured on CMR after 12
      months of intervention.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 7, 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Extracellular volume fraction (ECV)</measure>
    <time_frame>12 months</time_frame>
    <description>Absolute change in myocardial ECV, measured using CMR, from baseline to week 52</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular (LV) mass</measure>
    <time_frame>12 months</time_frame>
    <description>Absolute change in LV mass, measured using CMR, from baseline to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular volume</measure>
    <time_frame>12 months</time_frame>
    <description>Absolute change in LV volume, measured using CMR, from baseline to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>12 months</time_frame>
    <description>Absolute change in LV ejection fraction, measured using CMR, from baseline to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular strain - CMR</measure>
    <time_frame>12 months</time_frame>
    <description>Absolute change in LV strain, measured using CMR, from baseline to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular strain - Echo</measure>
    <time_frame>12 months</time_frame>
    <description>Absolute change in LV strain, measured using echocardiography, from baseline to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular torsion</measure>
    <time_frame>12 months</time_frame>
    <description>Absolute change in LV torsion, measured using echocardiography, from baseline to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial cell structure</measure>
    <time_frame>12 months</time_frame>
    <description>Absolute change myocardial cell volume, measured using CMR, from baseline to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic function</measure>
    <time_frame>12 months</time_frame>
    <description>Absolute change in LV diastolic function, measured using echocardiography, from baseline to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left atrial volume</measure>
    <time_frame>12 months</time_frame>
    <description>Absolute change in left atrial volume, measured using CMR, from baseline to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial energetic status</measure>
    <time_frame>12 months</time_frame>
    <description>Absolute change in myocardial energetic status (Phosphocreatine (PCr) to adenosine triphosphate (ATP) ratio), measured using Phosphorus-31 Magnetic Resonance Spectroscopy (31P MRS), from baseline to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac biomarkers - N-Terminal-Pro-Brain Natriuretic Peptide (NT-Pro BNP)</measure>
    <time_frame>12 months</time_frame>
    <description>Absolute change in NT-Pro BNP from baseline to week 13, baseline to week 26 and baseline to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac biomarkers - high-sensitivity Troponin T (hsTnT)</measure>
    <time_frame>12 months</time_frame>
    <description>Absolute change in hsTnT from baseline to week 13, baseline to week 26 and baseline to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient exercise capacity</measure>
    <time_frame>12 months</time_frame>
    <description>Absolute change in exercise tolerance, measured using 6 minute walk distance, from baseline to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient morbidity</measure>
    <time_frame>12 months</time_frame>
    <description>Absolute change in health status (quality of life), HF symptoms and physical limitations, measured using change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score, from baseline to week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>12 months</time_frame>
    <description>All cause mortality will be recorded but the trial is not powered for this clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiovascular mortality will be recorded but the trial is not powered for this clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation for heart failure</measure>
    <time_frame>12 months</time_frame>
    <description>Hospitalisation for heart failure will be recorded but the trial is not powered for this clinical outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cardiac Failure</condition>
  <arm_group>
    <arm_group_label>Pirfenidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pirfenidone 801mg capsule by mouth, three times a day (target dose) for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule by mouth, three times a day (target dose) for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>Pirfenidone is an orally bioavailable, small molecule antifibrotic agent.</description>
    <arm_group_label>Pirfenidone</arm_group_label>
    <other_name>Esbriet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule, manufactured with the exact components of the Pirfenidone capsules, without the active ingredient / investigational medicinal product</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent.

          2. Male or female; aged 40 years or older.

          3. HF, defined as one symptom present at the time of screening, and one sign present at
             the time of screening or in the previous 12 months. Symptoms and signs are defined as:

             Symptoms: dyspnoea on exertion, orthopnoea or paroxysmal nocturnal dyspnoea Signs:
             peripheral oedema, crackles on chest auscultation post-cough, raised jugular venous
             pressure or chest x-ray demonstrating pleural effusion, pulmonary congestion, or
             cardiomegaly

          4. Left Ventricular Ejection Fraction (LVEF) &gt; 45% at Visit 0, (any local LVEF
             measurement made using echocardiography or CMR).

          5. BNP ≥ 100 pg/ml or NTproBNP ≥ 300 pg/ml recorded at Visit 0. For patients in atrial
             fibrillation on Visit 0 ECG, BNP &gt; 300pg/ml or NTproBNP &gt; 900 pg/ml at Visit 0.

          6. Myocardial fibrosis, defined as Extracellular Matrix (ECM) volume &gt; 27% by CMR at
             Visit 0.

        Exclusion Criteria:

          1. Myocardial infarction, coronary artery bypass graft surgery or percutaneous coronary
             intervention within the previous 6 months.

          2. Probable alternative cause of patient's HF symptoms that in the opinion of the
             investigator primarily accounts for patient's dyspnoea such as significant pulmonary
             disease, anaemia or obesity. Specifically, patients with the below are excluded:

               1. Severe chronic obstructive pulmonary disease (COPD) (i.e., requiring home oxygen,
                  chronic nebuliser therapy, or chronic oral steroid therapy), or

               2. Haemoglobin &lt; 9 g/dl, or

               3. Body mass index (BMI) &gt; 55 kg/m2.

          3. Known pericardial constriction, genetic hypertrophic cardiomyopathy, or infiltrative
             cardiomyopathy.

          4. Clinically significant congenital heart disease.

          5. Presence of severe valvular heart disease.

          6. Atrial fibrillation or flutter with a resting ventricular rate &gt; 100 bpm.

          7. Any medical condition, which in the opinion of the Investigator, may place the patient
             at higher risk from his/her participation in the study, or is likely to prevent the
             patient from complying with the requirements of the study or completing the study.

          8. Severe renal dysfunction at Visit 0, defined as estimated Glomerular Filtration Rate
             (eGFR) &lt;30 mL/min (using Chronic Kidney Disease Epidemiology Collaboration Equation
             (CKD-EPI) calculation), or end-stage renal disease requiring dialysis.

          9. History of severe hepatic impairment or liver dysfunction at Visit 0, defined as total
             bilirubin above the upper limit of normal (ULN) (excluding patients with Gilbert's
             syndrome), aspartate aminotransferase (AST) or alanine transaminase (ALT) &gt;3 times the
             ULN or alkaline phosphatase &gt;2.5 times the ULN.

         10. Prolonged corrected QT interval, defined as a corrected QT interval &gt;500 msec on ECG
             using Bazett formula.

         11. Known hypersensitivity to any of the components of the investigational medicinal
             product (IMP).

         12. Use of other investigational drugs at the time of enrolment, or within 30 days or 5
             half-lives of enrolment, whichever is longer.

         13. Fluvoxamine use within 28 days of Visit 0.

         14. Contraindication to MRI scanning or gadolinium-based contrast agent

         15. Pregnancy, lactation or planning pregnancy. Women of childbearing capacity are
             required to have a negative serum pregnancy test before treatment, must agree to
             pregnancy tests at study visits as defined in the Section 7.2.5 and must agree to
             maintain highly effective contraception during the study and for 3 months thereafter.
             Similarly male participants with female partners of childbearing potential must agree
             to maintain highly effective contraception during the study and for 3 months
             thereafter.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher A Miller, MBChB, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manchester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher A Miller, MBChB, PhD</last_name>
    <phone>00441612914560</phone>
    <email>christopher.miller@manchester.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gavin A Lewis, MBChB</last_name>
    <phone>00441612914075</phone>
    <email>gavin.lewis-2@manchester.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Central Manchester University Hospital NHS Trust</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Colin Cunnington, MBChB, DPhil</last_name>
      <phone>0161 276 4271</phone>
      <email>colin.cunnington@cmft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of South Manchester</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher A Miller, MBChB PhD</last_name>
      <phone>0044 161 2914560</phone>
      <email>christopher.miller@manchester.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Gavin A Lewis, MBChB</last_name>
      <phone>0044 161 2914075</phone>
      <email>gavin.lewis-2@manchester.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010 Apr;35(4):821-9. doi: 10.1183/09031936.00005209. Epub 2009 Dec 8.</citation>
    <PMID>19996196</PMID>
  </reference>
  <reference>
    <citation>King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18. Erratum in: N Engl J Med. 2014 Sep 18;371(12):1172.</citation>
    <PMID>24836312</PMID>
  </reference>
  <reference>
    <citation>Van Erp C, Irwin NG, Hoey AJ. Long-term administration of pirfenidone improves cardiac function in mdx mice. Muscle Nerve. 2006 Sep;34(3):327-34.</citation>
    <PMID>16770778</PMID>
  </reference>
  <reference>
    <citation>Yamazaki T, Yamashita N, Izumi Y, Nakamura Y, Shiota M, Hanatani A, Shimada K, Muro T, Iwao H, Yoshiyama M. The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice. Hypertens Res. 2012 Jan;35(1):34-40. doi: 10.1038/hr.2011.139. Epub 2011 Aug 25.</citation>
    <PMID>21866107</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Wu Y, Chen J, Zhao S, Li H. Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation. Cardiology. 2013;126(1):1-11. doi: 10.1159/000351179. Epub 2013 Jul 2.</citation>
    <PMID>23839341</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2016</study_first_submitted>
  <study_first_submitted_qc>October 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2016</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Heart failure with preserved ejection fraction (HFpEF)</keyword>
  <keyword>Myocardial fibrosis</keyword>
  <keyword>Extracellular volume fraction (ECV)</keyword>
  <keyword>Interstitial fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

